Literature DB >> 21062889

Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis.

Anne Marie Sbrocchi1, Frank Rauch, Margaret L Lawson, Stasia Hadjiyannakis, Sarah Lawrence, Murat Bastepe, Harald Jüppner, Leanne Marie Ward.   

Abstract

OBJECTIVE: Pseudohypoparathyroidism (PHP) is a heterogeneous disorder characterized by hypocalcemia and hyperphosphatemia resulting from selective renal resistance to parathyroid hormone (PTH). One autosomal dominant form of PHP type 1b (PHP-Ib) is most frequently caused by a maternally inherited 3-kb deletion within STX16, the gene encoding syntaxin 16. To date, increased bone mineral density (BMD) has been described only in PHP type 1a, and there is a lack of detailed information on bone histomorphometry in PHP-Ib. The objective of this report was to present trans-iliac static and dynamic histomorphometry in two brothers with the 3-kb deletion in the STX16 region and elevated BMD.
DESIGN: Observational study of two brothers (age 18.0 and 22.7 years) with the 3-kb STX16 deletion and increased BMD.
RESULTS: The brothers had elevated PTH (146 pg/ml (15.6 pmol/l) and 102 pg/ml (10.9 pmol/l); normal: 10-64 pg/ml (1.1-6.8 pmol/l)) and striking osteosclerosis (lumbar spine areal BMD Z-scores: +5.4 and +4.9). Bone histomorphometry showed marked elevations in cortical width for both brothers (241 and 209% of the mean result expected for age), with elevations in the bone formation rate on the endocortical (119 and 260% of the healthy mean) and trabecular (220 and 190% of mean) surfaces.
CONCLUSION: Our findings suggest that PTH in this PHP-Ib genotype can increase cortical thickness due to its anabolic effect on endocortical bone, and underscore the heterogeneity in the skeletal phenotype among patients with PHP-Ib.

Entities:  

Mesh:

Year:  2010        PMID: 21062889      PMCID: PMC3810006          DOI: 10.1530/EJE-10-0795

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  29 in total

Review 1.  Parathyroid hormone and periosteal bone expansion.

Authors:  A Michael Parfitt
Journal:  J Bone Miner Res       Date:  2002-10       Impact factor: 6.741

2.  Variations in the pattern of pubertal changes in boys.

Authors:  W A Marshall; J M Tanner
Journal:  Arch Dis Child       Date:  1970-02       Impact factor: 3.791

3.  Periosteal appositional bone growth from age two to age seventy in man. A tetracycline evaluation.

Authors:  B N Epker; H M Frost
Journal:  Anat Rec       Date:  1966-03

4.  Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type Ib.

Authors:  S R Tollin; S Perlmutter; J F Aloia
Journal:  J Bone Miner Res       Date:  2000-07       Impact factor: 6.741

5.  Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version.

Authors:  Cynthia L Ogden; Robert J Kuczmarski; Katherine M Flegal; Zuguo Mei; Shumei Guo; Rong Wei; Laurence M Grummer-Strawn; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

6.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

7.  Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS.

Authors:  Murat Bastepe; Leopold F Fröhlich; Geoffrey N Hendy; Olafur S Indridason; Robert G Josse; Hiroyuki Koshiyama; Jarmo Körkkö; Jon M Nakamoto; Arlan L Rosenbloom; Arnold H Slyper; Toshitsugu Sugimoto; Agathocles Tsatsoulis; John D Crawford; Harald Jüppner
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

8.  Skeletal responsiveness in pseudohypoparathyroidism. A spectrum of clinical disease.

Authors:  G S Kidd; M Schaaf; R A Adler; M N Lassman; H L Wray
Journal:  Am J Med       Date:  1980-05       Impact factor: 4.965

9.  Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.

Authors:  Yebin Jiang; Jenny J Zhao; Bruce H Mitlak; Ouhong Wang; Harry K Genant; Erik F Eriksen
Journal:  J Bone Miner Res       Date:  2003-11       Impact factor: 6.741

Review 10.  Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry.

Authors:  A Michael Parfitt
Journal:  Curr Opin Nephrol Hypertens       Date:  2003-07       Impact factor: 2.894

View more
  6 in total

Review 1.  Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues.

Authors:  Giovanna Mantovani; Anna Spada; Francesca Marta Elli
Journal:  Nat Rev Endocrinol       Date:  2016-04-22       Impact factor: 43.330

Review 2.  An update on the clinical and molecular characteristics of pseudohypoparathyroidism.

Authors:  Michael A Levine
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-12       Impact factor: 3.243

3.  Ain't No Sunshine When She's Gone: Pseudohypoparathyroidism Discovered in an Adult.

Authors:  C R van Rooijen; M B Kok; S Simsek; F Stam
Journal:  Case Rep Endocrinol       Date:  2012-04-03

Review 4.  Imprinting disorders in humans: a review.

Authors:  Merlin G Butler
Journal:  Curr Opin Pediatr       Date:  2020-12       Impact factor: 2.856

Review 5.  Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Aurora Garcia Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen A T Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Manasori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebeca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Horm Res Paediatr       Date:  2020-08-05       Impact factor: 2.852

Review 6.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.